TCHP — docetaxel + carboplatin + trastuzumab + pertuzumab (HER2+ neoadjuvant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-DOCETAXEL` `DRUG-CARBOPLATIN` `DRUG-TRASTUZUMAB` `DRUG-PERTUZUMAB`

ID	`REG-TCHP-NEOADJUVANT`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-BREAST-EARLY-2024` `SRC-NCCN-BREAST-2025`

Notes

Standard neoadjuvant for HER2+ stage II-III. pCR rate ~60-65% with TCHP. Path to KATHERINE-eligibility: residual disease post-neoadj → adjuvant T-DM1; pCR → continue trastuzumab + pertuzumab to 1 year total.

Used By

Indication

IND-BREAST-HER2-POS-EARLY-NEOADJUVANT - IND-BREAST-HER2-POS-EARLY-NEOADJUVANT